(ANNX) Annexon - Ratings and Ratios
Antibody, Fragment, Oral, Inhibitor, Protein
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 92.2% |
| Value at Risk 5%th | 138% |
| Relative Tail Risk | -9.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 45.83 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.441 |
| Beta | 1.102 |
| Beta Downside | 0.999 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.33% |
| Mean DD | 46.33% |
| Median DD | 45.71% |
Description: ANNX Annexon December 30, 2025
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biotech focused on complement-mediated inflammation. Its lead asset, ANX005-a full-length monoclonal antibody-has progressed to a Phase 3 trial in Guillain-Barré syndrome (GBS), completed Phase II in Huntington’s disease, and is in a Phase 2a study for amyotrophic lateral sclerosis (ALS). The pipeline also includes ANX007 (a Fab fragment) in Phase 3 for geographic atrophy, ANX1502 (an oral small-molecule inhibitor) in Phase 1 for autoimmune diseases, and ANX009 (a C1q-blocking Fab) in Phase 1 for lupus nephritis.
As of the latest 10-Q (Q2 2024), Annexon reported cash and cash equivalents of roughly $115 million, giving it an estimated 18-month runway at current burn rates (~$6 million per quarter). The company’s market capitalization hovers around $300 million, implying a price-to-sales multiple of ~12× based on its projected 2025 revenue from ANX005 (estimated $25-30 million if Phase 3 succeeds). The broader biotech sector benefits from a 7% CAGR in FDA-approved therapies targeting neuro-degenerative and ocular diseases, and a favorable capital-raising environment driven by sustained investor appetite for rare-disease pipelines.
Key uncertainties remain: the primary risk is the outcome of the ANX005 Phase 3 GBS trial, which would determine whether Annexon can achieve a commercial product and unlock milestone payments from partnership agreements. Additionally, the transition of ANX007 to market hinges on demonstrating a meaningful visual-function benefit in geographic atrophy, a space where recent competitors have faced regulatory setbacks. These drivers should be weighted against base-rate success probabilities for Phase 3 neurology trials (~30% historically).
For a data-rich, objective view of Annexon’s valuation assumptions and scenario analysis, you may find ValueRay’s analyst dashboard a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-207.0m TTM) > 0 and > 6% of Revenue (6% = 204.2k TTM) |
| FCFTA -0.77 (>2.0%) and ΔFCFTA -49.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4384 % (prev 6664 %; Δ -2279 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.77 (>3.0%) and CFO -176.4m > Net Income -207.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (149.1m) change vs 12m ago 6.57% (target <= -2.0% for YES) |
| Gross Margin 46.89% (prev 30.00%; Δ 16.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.12% (prev 1.28%; Δ -0.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -22.77 (EBITDA TTM -214.3m / Interest Expense TTM -9.51m) >= 6 (WARN >= 3) |
Altman Z'' -26.36
| (A) 0.65 = (Total Current Assets 192.8m - Total Current Liabilities 43.6m) / Total Assets 229.1m |
| (B) -3.79 = Retained Earnings (Balance) -869.1m / Total Assets 229.1m |
| warn (B) unusual magnitude: -3.79 — check mapping/units |
| (C) -0.71 = EBIT TTM -216.5m / Avg Total Assets 304.0m |
| (D) -12.84 = Book Value of Equity -869.1m / Total Liabilities 67.7m |
| Total Rating: -26.36 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.73
| 1. Piotroski 1.50pt |
| 2. FCF Yield -23.35% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.17 |
| 5. Debt/Ebitda 0.52 |
| 6. ROIC - WACC (= -86.21)% |
| 7. RoE -92.28% |
| 8. Rev. Trend 19.08% |
| 9. EPS Trend 80.35% |
What is the price of ANNX shares?
Over the past week, the price has changed by +2.54%, over one month by +31.98%, over three months by +118.85% and over the past year by +64.27%.
Is ANNX a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.3 | 109.2% |
| Analysts Target Price | 14.3 | 109.2% |
| ValueRay Target Price | 8.2 | 19.1% |
ANNX Fundamental Data Overview January 17, 2026
Revenue TTM = 3.40m USD
EBIT TTM = -216.5m USD
EBITDA TTM = -214.3m USD
Long Term Debt = 26.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.82m USD (from shortTermDebt, last quarter)
Debt = 26.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -112.5m USD (from netDebt column, last quarter)
Enterprise Value = 756.4m USD (918.2m + Debt 26.9m - CCE 188.7m)
Interest Coverage Ratio = -22.77 (Ebit TTM -216.5m / Interest Expense TTM -9.51m)
EV/FCF = -4.28x (Enterprise Value 756.4m / FCF TTM -176.6m)
FCF Yield = -23.35% (FCF TTM -176.6m / Enterprise Value 756.4m)
FCF Margin = -5188 % (FCF TTM -176.6m / Revenue TTM 3.40m)
Net Margin = -6082 % (Net Income TTM -207.0m / Revenue TTM 3.40m)
Gross Margin = 46.89% ((Revenue TTM 3.40m - Cost of Revenue TTM 1.81m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.30 (Enterprise Value 756.4m / Total Assets 229.1m)
Interest Expense / Debt = 11.52% (Interest Expense 3.10m / Debt 26.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -171.1m (EBIT -216.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.42 (Total Current Assets 192.8m / Total Current Liabilities 43.6m)
Debt / Equity = 0.17 (Debt 26.9m / totalStockholderEquity, last quarter 161.4m)
Debt / EBITDA = 0.52 (negative EBITDA) (Net Debt -112.5m / EBITDA -214.3m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -112.5m / FCF TTM -176.6m)
Total Stockholder Equity = 224.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -68.11% (Net Income -207.0m / Total Assets 229.1m)
RoE = -92.28% (Net Income TTM -207.0m / Total Stockholder Equity 224.3m)
RoCE = -86.17% (EBIT -216.5m / Capital Employed (Equity 224.3m + L.T.Debt 26.9m))
RoIC = -76.25% (negative operating profit) (NOPAT -171.1m / Invested Capital 224.3m)
WACC = 9.95% (E(918.2m)/V(945.1m) * Re(9.98%) + D(26.9m)/V(945.1m) * Rd(11.52%) * (1-Tc(0.21)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 38.08%
Fair Price DCF = unknown (Cash Flow -176.6m)
EPS Correlation: 80.35 | EPS CAGR: 97.96% | SUE: 4.0 | # QB: 1
Revenue Correlation: 19.08 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.34 | Chg30d=+0.090 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.19 | Chg30d=+0.090 | Revisions Net=+1 | Growth EPS=+13.8% | Growth Revenue=+0.0%
Additional Sources for ANNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle